ROCCI, LAURA
 Distribuzione geografica
Continente #
AS - Asia 403
NA - Nord America 122
EU - Europa 73
SA - Sud America 4
AF - Africa 3
OC - Oceania 1
Totale 606
Nazione #
SG - Singapore 326
US - Stati Uniti d'America 114
CN - Cina 42
IT - Italia 30
HK - Hong Kong 27
GB - Regno Unito 19
DE - Germania 9
CA - Canada 6
IN - India 4
NL - Olanda 4
EC - Ecuador 3
GH - Ghana 2
MX - Messico 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BR - Brasile 1
CZ - Repubblica Ceca 1
ES - Italia 1
FI - Finlandia 1
FR - Francia 1
HU - Ungheria 1
IE - Irlanda 1
JP - Giappone 1
LU - Lussemburgo 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
UA - Ucraina 1
Totale 606
Città #
Singapore 53
Boardman 29
Ashburn 26
Hong Kong 25
Hefei 19
London 18
Shanghai 11
San Francisco 7
Toronto 6
Rome 5
Amsterdam 4
Council Bluffs 4
Pune 4
Canzo 3
Milan 3
Tivoli 3
Accra 2
Ancona 2
Chieti 2
Florence 2
Hangzhou 2
Los Angeles 2
Natick 2
Washington 2
West Jordan 2
Andover 1
Ankara 1
Bethesda 1
Brno 1
Canberra 1
Cerveteri 1
Chengdu 1
Dongguan 1
Dubai 1
Dublin 1
Freetown 1
Helsinki 1
Lancaster 1
Lianyun 1
Luxembourg 1
Melilli 1
Portici 1
Redmond 1
Redwood City 1
San Gavino Monreale 1
Santa Teresa di Riva 1
Seattle 1
Shijiazhuang 1
St Louis 1
São Paulo 1
Tokyo 1
Vienna 1
Warsaw 1
West Chester 1
Wuxi 1
Totale 268
Nome #
Scientific Evidence for Non-Pharmacological Management of the Main Side-Effects of Antineoplastic Drugs in Colorectal Cancer Patients. [Evidenze scientifiche per la gestione non farmacologica dei principali effetti collaterali della terapia antineoplastica nei pazienti con cancro colon-rettale] 63
Survey on learning needs and preferred sources of information to meet these needs in Italian oncology patients receiving chemotherapy 40
Prospective observational multicentric case-control study about 'fatigue' in patients with history of breast cancer 39
S-Adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury 38
Meeting information needs on cancer-related fatigue: an exploration of views held by Italian patients and nurses 37
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients 32
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients 32
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan 32
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome 31
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients 30
Docetaxel induced pericardial effusion 30
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients 29
Fatal thrombocytopenia and thrombocytopathia: An unusual onset of non small cell lung cancer 29
In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients 28
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 28
Bisphosphonates: new antiangiogenic molecules in cancer treatment? 28
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients 26
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 20
Repeated intermittent low-dose therapy with zoledronic Acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients 19
Totale 611
Categoria #
all - tutte 7.268
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.268


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202257 0 0 5 1 1 2 2 4 2 3 3 34
2022/202318 4 1 6 0 0 0 0 2 2 1 2 0
2023/202487 4 8 2 11 8 30 1 12 1 4 2 4
2024/2025449 13 7 34 5 7 33 9 6 37 120 178 0
Totale 611